How This Evidence Evolved
Contrast-Associated AKI
Rethinking the paradigm of contrast nephropathy prevention
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
Follow-up studies, subgroup analyses, and real-world validation
Integration into clinical practice guidelines and recommendations
IV hydration not routine for stable eGFR ≥30 with IV contrast; consider AKI/high-risk exceptions; no NAC; preserve diagnostic contrast dose.
For routine repeated iodinated contrast: maintain 4 hours if eGFR >30; delay 48 hours if eGFR <30 mL/min/1.73 m². Emergency or life-threatening demand overrides these intervals.
Current standard of care and ongoing research directions
Landmark Trials in This Story
Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine
Creatinine rise ≥0.5 mg/dL at 48 h: NAC 2% vs placebo 21% (P=0.01)
Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine
Death, dialysis, or persistent ≥50% creatinine increase at 90 days: bicarbonate 4.4% vs saline 4.7% (p=0.62); NAC 4.6% vs placebo 4.5% (p=0.88)
Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial
CIN incidence: 2.6% no prophylaxis vs 2.7% IV hydration (noninferior); hydration complications in 5.5%
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.